November 21, 2016 7:50am
… Newest highs question the tenor of uncertainty
It’s complicated, after all the losses; don’t assume the worst, as the market is even less sure of whether “our” universe is going forward
… Futures struggle as a holiday shortened week
I answer one question; in which company should investors put, keep and commit their money!
If you are not a subscriber, you won’t know the morning’s indications and who is in the headlights.
I write in every line that investors need to avoid risks as if I were the first to be hurt if I am wrong!
RegMed Investors’ (RMi) provides exclusive and original content; put your eyes on the page to figure out what’s really going on!
I keep track of closes, indexes and pricing as news lately lacks any energy as the social media impact of RMi reporting stimulates the reality of “our” universe as well as disrupting element in the trading of sector equities!
BUY: IMUC
SELL: AGTC, AST, BLCM and CAPR
Indexes and ETFs: The IBB (-0.15%) and XBI (-0.58%) are DOWN, the IWM (+0.10%) is UP while the XLV is NOT indicating
Dow futures are DOWN -0.19% and NASDAQ futures are DOWN -0.23%
U.S. stock index futures are poised to open flat to higher on Monday morning, ahead of a four-day Thanksgiving trading week, as traders anticipated comments from Fed Vice Chairman Fischer.
European markets were mixed as dollar strength took a breather and oil prices jumped.
Asian markets traded mixed as dollar strength took a breather and oil prices surged.
Data docket: The Chicago Fed national activity index due at 8:30 a.m. ET. The bulk of the week’s economic indicators are expected Wednesday, which brings an update on durable goods orders and the minutes of the latest Federal Open Market Committee meeting.
- Federal Reserve Vice Chairman Stanley Fischer is due to speak on the longer-term challenges facing the U.S. in New York at 8 a.m. ET
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Friday and Thursday, NEGATIVE Wednesday and Tuesday and POSITIVE last Monday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
· Friday closed POSITIVE with 17 decliners, 24 advancers and 2 flats;
· Thursday closed POSITIVE with 15 decliners, 28 advancers and 0 flats;
· Wednesday closed NEGATIVE with 26 decliners, 13 advancers and 4 flats;
· Tuesday closed NEGATIVE with 27 decliners, 13 advancers and 3 flats;
· Last Monday closed POSITIVE with 17 decliners, 22 advancers and 4 flats;
Remembering Friday’s closing investor letter, “In relation to the upside versus the downside; the gap widened and closed in two days followed by the reverse <… a positive close>.”
- As I had stated, “Vulnerability is today’s buzz word! “Our” universe is always in some sort of sentiment pain, as the sharply up and painfully down syndrome seems to never leave.”
The election win has dribbled the SCG&RT sector up and then down as the reality of uncertainty returned.
- Since Election Day and the surprise presidential election win for Donald Trump, the Dow has climbed 2.9%, the S&P 500 has gained 2%, and the Nasdaq has risen 2.5%.
While the Russell 2000 index of small-cap stocks surged to its longest win streak in 13 years and retail investors swung to the most bullish they have been in nearly two years – the question is HOW long will it continue?
- One thing to note is how the SCG&RT sector has jumped and recoiled following the election and how that will continue to trade? Answer, in tight ranges … as highs have a way of depreciating!
A pause for reflection could come in a week where volume traditionally thins out as traders head out for the Thanksgiving Day holiday. Markets will shut Thursday and then close early on Black Friday, the traditional kickoff to holiday shopping.
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
· The iShares Nasdaq Biotechnology (IBB) closed Friday down -1.32% and is DOWN -0.15% in Monday’s pre-market;
· The SPDR S&P Biotech ETF (XBI) closed Friday down -0.75% and is DOWN-0.58% in Monday pre-market;
· The Health Care Select Sector SPDR ETF (XLV) closed down -1.06% Friday and is NOT indicating in Monday’s pre-market;
· The iShares Russell 2000 (IWM) closed up +0.53% on Friday and is UP +0.10% in Monday’s pre-market.
Companies in my headlights:
Applied Genetic technologies (AGTC) closed UP +$.045 to $10.05. Up, down, reverse and forward, the retail component of the share’s pricing is erratic as the shares have traded last week - $9.60 <Thursday>, $9.35 <Wednesday>, $10.10 <Tuesday>and Monday’s $10.55. The previous week ranged from $7.20 to $9.85 – time for another rotation for profit taking – SELL;
Asterias Biotherapeutics (NYSEMKT: AST) closed UP again +$0.11 to $5.56 after Thursday’s $5.45 (+$0.65) after Wednesday’s $4.80 (+$0.40). Since 11/8’s $3.05 to 11/15’s <Tuesday> $4.40, a target is being formed for trading – Maintaining SELL;
Bellicum Pharmaceuticals (BLCM) closed UP +$0.49 to $22.52. Momentum traders catch the essence of a trade, as the week staggered across trades $22.02 <Thursday>, $21.95 <Wednesday>, $22.32 <Tuesday>, and Monday’s $22.69. While the previous week 11/4-7 laid the course at $17.75 to $22.14 SELL;
Capricor (CAPR) closed UP +$0.06 to $3.15. After a decent week of Thursday’s $3.09, Wednesday’s $2.95, Tuesday’s $3.00 and Monday’s $3.11 while the previous week’s ranged from $2.66 to $2.87. I’d SELL to come back … I still have questions re their spending and the issue of patent filling on their newest quest for exosomes; also the Janssen (J&J) option is yet to be secured …
ImmunoCellular (NYSEMKT: IMUC) closed DOWN -$0.0046 to $0.065 IMUC common stock and listed warrants will begin trading Monday on the NYSE MKT on a split-adjusted basis – a one-for-forty reverse stock split. Concurrently, the authorized number of shares of IMUC's common stock will be reduced from 249 M to 25 M. It will be considered a BUY on the split basis but, watch for the downside focus …
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
